CYDY - CytoDyn: When More Is Less

I first became interested in CytoDyn (CYDY) in February 2019. I was skeptical of its seemingly overblown claims and wrote an article for Seeking Alpha titled, "CytoDyn: What To Do When It's Too Good To Be True?".

As matters now stand, the situation seems dire. CytoDyn is pursuing too many diverse opportunities and has too little liquidity with which to develop them.

CytoDyn's lead therapy is PRO 140 in treatment of HIV, which it claims to have blockbuster potential. Instead of focusing all its efforts in a balls to the wall

Read more ...